Related Experiment Video
Updated: May 26, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Using metadynamics and path collective variables to study ligand binding and induced conformational transitions.
Neva Bešker1, Francesco L Gervasio
1Spanish National Cancer Research Centre, Madrid, Spain.
Methods in Molecular Biology (Clifton, N.J.)
|December 21, 2011
Summary
Computational drug design can overcome challenges of target flexibility. Advanced molecular dynamics and free energy methods enable rational design of potent drugs targeting flexible proteins like cyclin-dependent kinases for cancer therapy.
Area of Science:
- Computational chemistry and structural biology.
- Drug discovery and medicinal chemistry.
Background:
- Large-scale conformational transitions in drug targets pose challenges for computational drug design.
- Understanding target flexibility is crucial for developing potent and selective drug candidates.
Purpose of the Study:
- To discuss computational methods for studying large-scale conformational transitions in flexible drug targets.
- To explore the application of these methods in rational drug design.
Main Methods:
- Utilizing molecular dynamics simulations.
- Employing free energy algorithms, including Metadynamics and Path Collective Variables.
- Analyzing ligand binding to flexible targets.
Main Results:
- Demonstrated the capability of molecular dynamics and free energy methods to study conformational transitions.
- Showcased the application of these techniques to flexible targets like cyclin-dependent kinases.
- Provided real-life examples of successful application in drug design.
Conclusions:
- Molecular dynamics combined with advanced free energy algorithms can effectively study target flexibility.
- These computational approaches offer opportunities to rationally design more effective drugs for challenging targets.
- Cyclin-dependent kinases serve as a promising example for cancer therapeutic development using these methods.
Related Concept Videos
02:18The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
01:58Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
01:58Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
01:58Cooperative Allosteric Transitions
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...